Cero Therapeutics Holdings, Stock Performance
| CERO Stock | 0.06 0.01 19.00% |
CERo Therapeutics holds a performance score of 4 on a scale of zero to a hundred. The firm shows a Beta (market volatility) of 0.89, which signifies possible diversification benefits within a given portfolio. CERo Therapeutics returns are very sensitive to returns on the market. As the market goes up or down, CERo Therapeutics is expected to follow. Use CERo Therapeutics maximum drawdown, as well as the relationship between the expected short fall and rate of daily change , to analyze future returns on CERo Therapeutics.
Risk-Adjusted Performance
4 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in CERo Therapeutics Holdings, are ranked lower than 4 (%) of all global equities and portfolios over the last 90 days. In spite of very fragile basic indicators, CERo Therapeutics displayed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Disposition of 1002 shares by Brian Atwood of CERo Therapeutics subject to Rule 16b-3 | 09/25/2024 |
2 | Cero Therapeutics cancels special stockholder meeting - Investing.com | 09/26/2024 |
3 | Disposition of 1317956 shares by Brian Atwood of CERo Therapeutics at 1.77 subject to Rule 16b-3 | 09/30/2024 |
4 | Insider Trading | 10/01/2024 |
5 | Crude Oil Down 3 Aramark Posts Upbeat Earnings | 11/11/2024 |
6 | Nasdaq Tumbles Over 200 Points Alibaba Posts Upbeat Sales | 11/15/2024 |
7 | CERo Therapeutics Holdings Inc. reports earnings - Quartzy | 11/19/2024 |
8 | Acquisition by Patel Shami of 127500 shares of CERo Therapeutics at 0.0951 subject to Rule 16b-3 | 12/02/2024 |
9 | Disposition of 850543 shares by Yk Bioventures Opportunities Gp I, Llc of CERo Therapeutics at 0.11 subject to Rule 16b-3 | 12/09/2024 |
10 | Disposition of 1570947 shares by Yk Bioventures Opportunities Gp I, Llc of CERo Therapeutics at 0.09 subject to Rule 16b-3 | 12/10/2024 |
11 | Disposition of 1614541 shares by Yk Bioventures Opportunities Gp I, Llc of CERo Therapeutics at 0.07 subject to Rule 16b-3 | 12/12/2024 |
12 | Disposition of 2998908 shares by Yk Bioventures Opportunities Gp I, Llc of CERo Therapeutics at 0.06 subject to Rule 16b-3 | 12/13/2024 |
| Begin Period Cash Flow | 42.1 K | |
| Free Cash Flow | -1519.60 |
CERo |
CERo Therapeutics Relative Risk vs. Return Landscape
If you would invest 8.40 in CERo Therapeutics Holdings, on September 15, 2024 and sell it today you would lose (2.73) from holding CERo Therapeutics Holdings, or give up 32.5% of portfolio value over 90 days. CERo Therapeutics Holdings, is currently generating 1.5353% in daily expected returns and assumes 27.0402% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than CERo, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
CERo Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for CERo Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as CERo Therapeutics Holdings,, and traders can use it to determine the average amount a CERo Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0568
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | CERO | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 27.04 actual daily | 96 96% of assets are less volatile |
Expected Return
| 1.54 actual daily | 30 70% of assets have higher returns |
Risk-Adjusted Return
| 0.06 actual daily | 4 96% of assets perform better |
Based on monthly moving average CERo Therapeutics is performing at about 4% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of CERo Therapeutics by adding it to a well-diversified portfolio.
CERo Therapeutics Fundamentals Growth
CERo Stock prices reflect investors' perceptions of the future prospects and financial health of CERo Therapeutics, and CERo Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on CERo Stock performance.
| Return On Asset | -0.45 | ||||
| Current Valuation | 12.73 M | ||||
| Shares Outstanding | 51.35 M | ||||
| EBITDA | (2.44 M) | ||||
| Net Income | (2.54 K) | ||||
| Total Debt | 1.55 M | ||||
| Book Value Per Share | (0.52) X | ||||
| Cash Flow From Operations | (1.52 K) | ||||
| Earnings Per Share | (1.19) X | ||||
| Market Capitalization | 4.79 M | ||||
| Total Asset | 8.56 M | ||||
| Retained Earnings | (14.2 M) | ||||
| Working Capital | 5.91 M | ||||
About CERo Therapeutics Performance
By examining CERo Therapeutics' fundamental ratios, stakeholders can obtain critical insights into CERo Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that CERo Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Capital Employed | (0.87) | (0.82) |
Things to note about CERo Therapeutics performance evaluation
Checking the ongoing alerts about CERo Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for CERo Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| CERo Therapeutics is way too risky over 90 days horizon | |
| CERo Therapeutics has some characteristics of a very speculative penny stock | |
| CERo Therapeutics appears to be risky and price may revert if volatility continues | |
| CERo Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| CERo Therapeutics Holdings, was previously known as Phoenix Biotech Acquisition and was traded on NASDAQ Exchange under the symbol PBAX. | |
| Net Loss for the year was (2.54 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| CERo Therapeutics generates negative cash flow from operations | |
| CERo Therapeutics has a frail financial position based on the latest SEC disclosures | |
| About 13.0% of the company shares are held by company insiders | |
| Latest headline from thelincolnianonline.com: Disposition of 2998908 shares by Yk Bioventures Opportunities Gp I, Llc of CERo Therapeutics at 0.06 subject to Rule 16b-3 |
- Analyzing CERo Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether CERo Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining CERo Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating CERo Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of CERo Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of CERo Therapeutics' stock. These opinions can provide insight into CERo Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CERo Therapeutics Holdings,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of CERo Therapeutics. If investors know CERo will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about CERo Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.19) | Return On Assets (0.45) |
The market value of CERo Therapeutics is measured differently than its book value, which is the value of CERo that is recorded on the company's balance sheet. Investors also form their own opinion of CERo Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is CERo Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because CERo Therapeutics' market value can be influenced by many factors that don't directly affect CERo Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between CERo Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if CERo Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, CERo Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.